Most Read Articles
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.

NAFLD risk, remission influenced by lifestyle

29 Jan 2020

Lifestyle factors, such as weight gain, smoking and exercise, appear to affect the development and remission of nonalcoholic fatty liver disease (NAFLD), reports a recent study.

Researchers performed a longitudinal cohort study including 1,421 participants (mean age, 53.0±11.9 years; 50.0 percent male) whose only cause of liver disease was NAFLD. At baseline, 34.1 percent (n=484) were diagnosed with NAFLD. Participants were followed for a mean of 4.6±2.8 years, during which time they had a mean of 4.8±2.7 checkup visits each.

Over the follow-up period, 11.1 percent (n=104) of the 937 patients who were free of NAFLD at baseline developed the disease at a rate of 2.4 percent per year. On the other hand, 26.2 percent of those with NAFLD at baseline achieved remission.

Multivariate analysis found that males were at a significantly greater risk of developing NAFLD (adjusted odds ratio [OR], 2.07, 95 percent confidence interval [CI], 1.35–3.21). The same was true for a longer follow-up period (adjusted OR, 1.11, 1.03–1.20), having dyslipidaemia (adjusted OR, 2.39, 95 percent CI, 1.25–4.56) and smoking cessation (adjusted OR, 2.86, 95 percent CI, 1.24–6.62).

In the study, participants who quit smoking were more likely to demonstrate large gains in weight (p<0.001) which, in turn, correlated with a stronger risk of NAFLD (p<0.001). Failing to lose weight was likewise a significant risk factor (adjusted OR, 0.30, 0.18–0.50). In contrast, weight loss significantly increased the chances of NAFLD remission (adjusted OR, 2.83, 95 percent CI, 1.80–4.44).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 07 Feb 2020
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.